SM
RPRX icon

Samantha McLemore’s Royalty Pharma RPRX Stock Holding History

Samantha McLemore’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202M Sell
3,598,808
-44,908
-1% -$2.34M 6.61% 1
2026
Q1 		$175M Buy
3,643,716
+310,041
+9% +$13.6M 6.39% 1
2025
Q4 		$129M Buy
3,333,675
+215,825
+7% +$8.23M 4.97% 4
2025
Q3 		$110M Buy
3,117,850
+129,862
+4% +$4.7M 4.4% 8
2025
Q2 		$108M Buy
2,987,988
+15,342
+0.5% +$508K 4.86% 5
2025
Q1 		$92.5M Buy
2,972,646
+97,557
+3% +$3.09M 4.76% 5
2024
Q4 		$73.3M Buy
2,875,089
+833,894
+41% +$22.1M 3.38% 10
2024
Q3 		$57.7M Buy
2,041,195
+616,805
+43% +$17.1M 2.84% 15
2024
Q2 		$37.6M Buy
1,424,390
+4,572
+0.3% +$127K 1.99% 26
2024
Q1 		$43.1M Buy
1,419,818
+165,038
+13% +$4.87M 2.1% 26
2023
Q4 		$35.2M Buy
+1,254,780
New +$34.5M 1.87% 27

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samantha McLemore's RPRX Position: Q2 2026 in Review

Samantha McLemore reduced its Royalty Pharma (RPRX) stake by 1.2% in Q2 2026, selling an estimated $2.34M and leaving 3,598,808 shares worth $202M. The position accounts for 6.61% of the portfolio, ranked #1.

Samantha McLemore first reported a position in RPRX in Q4 2023 and has held it in 11 quarters since. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Samantha McLemore held 3,598,808 shares of Royalty Pharma worth $202M as of Q2 2026.
  • Samantha McLemore sold 44,908 Royalty Pharma shares in Q2 2026, an estimated $2.34M.
  • Royalty Pharma made up 6.61% of Samantha McLemore's portfolio in Q2 2026, its #1 holding.
  • Samantha McLemore first reported a position in Royalty Pharma in Q4 2023 and has held it in 11 quarters since.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Patient Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.